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Abstract: Several modes of vaccine delivery have been developed in the last 25 years, which induce
strong immune responses in pre-clinical models and in human clinical trials. Some modes of delivery
include, adjuvants (aluminum hydroxide, Ribi formulation, QS21), liposomes, nanoparticles, virus
like particles, immunostimulatory complexes (ISCOMs), dendrimers, viral vectors, DNA delivery
via gene gun, electroporation or Biojector 2000, cell penetrating peptides, dendritic cell receptor
targeting, toll-like receptors, chemokine receptors and bacterial toxins. There is an enormous amount
of information and vaccine delivery methods available for guiding vaccine and immunotherapeutics
development against diseases.
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1. Introduction
The first attempts to prevent infectious diseases was over 1000 years ago in China, whereby
contents of smallpox vesicles were injected into people who had not previously experienced smallpox.
Fatalities were uncommon in the individuals inoculated with the smallpox vesicles, compared with
victims of natural smallpox infection. More than 700 years later, Edward Jenner injected an 8 year old
boy with cowpox and challenged him with smallpox, the boy was subsequently protected against
smallpox. Hence the term “cross reactivity” was coined. Two hundred years later, smallpox vaccination
became increasingly popular in the decade 1967–1977 and complete world-wide eradication was
accomplished. Remarkably, the Jennerian approach to immunoprophylaxis remains valid. It should be
noted that Louis Pasteur, himself one of the great vaccinologists, coined the term “vaccine” in honor of
Jenner, to refer to immunizing agents.
Numerous methods of vaccination have been used, such as: attenuated bacteria, live viruses, dead
organisms and despite their success, a number of disasters in humans have resulted. Disasters were
primarily due to improper lab manufacturing and handling and consequently these incidences led
to improved procedures and the safety of vaccines, and led to regulatory measures to assure proper
laboratory conditions. With attempts to control more complex diseases and the need to improve
vaccine safety, stability, efficacy and cost, there is pressure for precisely defined vaccines.
Public awareness of health and safety issues vaccines must now meet higher standards of safety
and biochemical characterization than they did in the past. Some of the vaccines developed in the past
would not even meet the minimum standards required today. Hence, new improved precisely defined
highly purified vaccines need to be developed. Advances in fields such as peptide synthesis, molecular
biology, protein production, crystallography, cell biology, immunology and animal models are required
for the development of new and improved vaccines, in an attempt to move from traditional live
virus vaccines to the theoretical safer but “less immunogenic” vaccines. In an attempt to improve the
immunogenicity of the highly purified vaccines, a number of technologies and delivery methods have
been developed over the years, in order to deliver antigens to induce appropriate responses.
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2. Vaccination
The biggest triumph in the history of vaccination, was the eradication of smallpox, and it was
achieved without a specific delivery vehicle, and without detailed knowledge of immune cell activation.
Interestingly, Edward Jenner injected people with cowpox vesicles at the back of a hut at his home,
“Jenner’s hut”, where no, good laboratory practice (GLP) and good manufacturing practice (GMP)
regulations were in place (Figure 1). Today, the immunizing antigen must be clearly defined, can’t
be a crude extract, epitopes identified, a delivery method used, evidence that the vaccine induces an
immune response in pre-clinical models. For a vaccine to be used and injected into an individual,
endless amounts of paperwork are required and vaccines must meet GLP and/or GMP quality and
clinical trials to be conducted under good clinical practice (GCP) guidelines. How many of the vaccines
produced today, have eradicated a disease? Is it because safer and more precise vaccines are required?
Or is it, because no worldwide mass vaccinations have occurred, since smallpox? Perhaps the public
awareness and regulations put in place in most countries for compulsory injections of measles, mumps,
rubella (MMR) vaccinations in infants and chickenpox vaccine in toddlers, may lead to their eradication
within the next generation.
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3. Technologies Used in the Generation of New Improved Vaccines
The application of genetic and recombinant DNA approaches to vaccination has led to new
possibilities of safer and more efficient vaccines. Recombinant DNA technology can be applied to
antigen identification and isolation, and by being able to clone and express all the antigens of an
organism individually, overcomes two major hurdles associated with traditional vaccines. First, before
the recombinant DNA era, it was difficult to obtain sufficient quantities of particular antigens in a pure
enough form to allow the appropriate testing. Recombinant DNA technology overcame this problem,
and second, recombinant DNA technology has made the study of pathogenic organisms safer because
single genes and their translation products are examined rather than the whole organism [1–3].
Synthetic peptide chemistry has greatly contributed to vaccinology, where peptides
(2–100 amino acids) could be synthesized and used as immunogens, in addition to synthesizing T and
B cell epitopes and used as vaccines. Nuclear magnetic resonance (NMR), molecular modelling and
X-ray crystallography approaches in understanding protein structures has contributed enormously
into the generation of improved vaccines. Numerous peptide based vaccines have been shown
effective in pre-clinical and in human clinical trials [4–7]. The advent of these technologies stimulated
the production of new vaccines and the identification of precise epitopes on antigens has made
synthetic peptide vaccines a real possibility. Such vaccines are designed to be safer and more efficient.
Unfortunately, there are still many obstacles for their clinical use; the limited immunogenicity of many
of these candidates has hindered their development as potential vaccines. Strategies to enhance the
immunogenicity of candidate vaccines are therefore required.
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4. Methods of Vaccine Delivery: Approaches to Enhancing Immunogenicity
Adjuvants have the ability to amplify either or both humoral and cellular immune responses to
an antigen. The most commonly used adjuvant in experimental animals is complete and incomplete
Freund’s adjuvant, and, although very effective in evoking effective and long lasting immune response,
it is not suitable for human use. There is only one registered human adjuvant (aluminum hydroxide or
aluminum phosphate) which is used in diphtheria, tetanus and hapatitis B vaccines. Aluminum salt
adjuvants are limited in their use, in that they preclude lyophilisation or freezing, they are not effective
with all antigens and they do not stimulate cell-mediated immunity. Candidates for alternative
adjuvants for vaccine development, include, the Syntex formulation, SAF-1 (containing squalene
oil, an amino acid derivative of muramyl dipeptide (threonyl-MDP) and nonionic block polymers),
Ribi formulation (containing mycobacterial cell walls and monophosphoryl lipid A) and saponin
derivative, QS21 [8].
Liposomes (phospholipid-based vesicles) were extensively used in the 1970s to deliver or
target drugs to specific sites in the body. An additional promising aspect of the system is
its immunoadjuvant action, shown to induce humoral and/or cell-mediated immune responses
for liposome-entrapped antigens with or without cytokines or other immunological active
agents [9]. Another approach involves incorporation of antigens into solid particles called ISCOMs
(immunostimulatory complexes). ISCOMs are composed of the adjuvant Quil A and peptides.
ISCOM particles contain low concentrations of adjuvant and can therefore significantly enhance
immunogenicity of an antigen [10,11].
The multiple antigen peptide approach (MAP), also known as dendrimers, is aimed at replacing a
protein carrier in a peptide based vaccine, with a small structural unit that can amplify peptide antigens
without the disadvantages associated with protein carriers. The framework of the MAP is a core matrix
consisting of branching trifunctional amino acids (such as, lysine) with the following properties:
(i) non-immunogenic; (ii) ability to amplify the peptide antigens into a macromolecule; (iii) flexibility to
incorporate multiple epitopes and (iv) accessible for chemical synthesis. MAP (dendrimer) technology
has been used to successfully induce immune responses to antigens [12,13].
The ideal vaccine for many diseases is a live attenuated derivative of the pathogen which can
induce protective immunity to antigens on the pathogen without causing any side effects. Barriers to
the development of such vaccines, however, give rise to difficulties in growing the pathogen in
the laboratory and difficulties in attenuating the pathogen. One strategy of overcoming these
barriers is to insert the pathogen’s genes into a nonpathogenic organism. The non-virulent organism
(recombinant virus) serves as a vector for the expression of the genes coding for the antigens. This has
the advantage that the recombinant virus simultaneously synthesizes the foreign antigen and delivers
it to the host’s immune system. Several vectors have been tested in the development as vaccines,
such as, vaccinia virus, vaccinia virus ankara, avipoxvirus, adenovirus, alphavirus and enterovirus
vectors [14,15].
Immunization with non-replicating plasmid DNA (“naked DNA”) encoding viral proteins may
be advantages to use as vaccines, because no infectious agent is involved, there is no requirement for
assembly of virus particles and determinant selection is permitted. In animal models strong immune
responses were generated; however, these did not translate into human clinical trials. As a result
delivery methods for DNA were required, and as such, in vitro and in vivo electroporation, gene-gun
and Biojector 2000 were developed. Other modes of delivery include, non-viral vectors and receptor
mediated uptake of DNA into cells [16,17].
Cell penetrating peptides (CPP) or membrane translocating peptides (MTP) are a group of cationic
peptides that have the ability to enter into the cytoplasm of cells. CPP are able to deliver a number
of antigens, including RNA, DNA, peptides, proteins, drugs and virus particles into cells. In fact,
CPP (i) TAT from the human immunodeficiency virus transactivator of transcription protein and
(ii) penetratin from the Drosophila Antennapedia domain have been used to deliver antigens with strong
cellular and antibody response induction[18].
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In addition, an array of other methods of vaccine delivery have shown great promise in animal
models and in human clinical trials. Such methods include, use of nanoparticles, virus-like particles,
use of ex vivo grown monocyte derived dendritic cells and targeting antigens to dendritic cell receptors
such as, c-type lectin receptors, mannose receptor, DC-SIGN, DEC205, L-SIGN, DC-SIGNR, CIRE,
FIRE, Langerin, MGL, dectin-1, dectin-2, DNGR-1, Clec12A, Clec12B, Clec2, LOX1, DCIR, scavenger
receptor, F4/80 receptor, DC-STAMP and Fc receptor [19,20]. More recently, there has been an upsurge
of information regarding toll-like receptor (TLR) targeting and stimulation of DCs via TLR. In mice,
TLR ligands activate DCs and elicit immune responses [21–23], however, no substantial TLR-targeting
vaccine trials have been completed in humans and it is unknown whether TLR targeted approach
will result in significant benefits in humans as those seen in mice. Moreover, targeting antigens to
chemokine receptors on DCs (CCR1, CCR2, CCR5, CCR6, CXCR1, CXCR4) have shown to generate
strong immune responses in vitro and in vivo. Furthermore, bacterial toxins and DC binding peptides
target antigens to DCs without the requirement of DC receptor targeting [20]. In the special issue of
“Vaccine delivery”, the latest methods of, live-attenuated bacterial vectors [24], nanoparticle based
vaccines [25,26], synthetic carriers [27], cholera toxin subunit B as an adjuvant [28] and Gavi vaccination
programs [29], are extensively reviewed.
5. Conclusions
Over the last 25 years, vaccine delivery methods have been developed to induce immune
responses to the highly purified and ‘safe’ vaccines. Numerous methods induce strong cellular,
humoral and/or protection in animal models, and are rapidly moving into human clinical trials.
We await the outcomes that will show which vaccine delivery method will ultimately prove useful in
eradicating disease.
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